Nobody is guaranteeing anything other than 13D is better positioned to to better for the drug. There is no guarantee that the FDA will approve Leronlimab even with a properly submitted BLA. I think that 13 D is motivated to get a proper BLA submitted right their first time.
NP has a track record with CYDY.Total failure, theft and lies. It is all about LL and NP has no approvals. Despite successful HIV trial, approval is no closer than in 2020. It was virtually ignored in the CC this week despite a timeline set in stone by NP this summer for resubmission.
The current management track record is one of demonstrative failures and zero accountability by the BOD.
What could be worse. Management is pissing millions away to save their skins. They do not want anyone to see the schemes behind the curtain.
News 
Market Data 
Discover 
AI
